DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Eunhye | ko |
dc.contributor.author | Lee, Jinju | ko |
dc.contributor.author | Lee, In-Hyun | ko |
dc.contributor.author | Yu, Mikyung | ko |
dc.contributor.author | Kim, Hyungjun | ko |
dc.contributor.author | Chae, Su Young | ko |
dc.contributor.author | Jon, Sangyong | ko |
dc.date.accessioned | 2014-12-09T01:31:57Z | - |
dc.date.available | 2014-12-09T01:31:57Z | - |
dc.date.created | 2014-08-29 | - |
dc.date.created | 2014-08-29 | - |
dc.date.issued | 2008-10 | - |
dc.identifier.citation | JOURNAL OF MEDICINAL CHEMISTRY, v.51, no.20, pp.6442 - 6449 | - |
dc.identifier.issn | 0022-2623 | - |
dc.identifier.uri | http://hdl.handle.net/10203/192418 | - |
dc.description.abstract | A new platform for oral delivery of paclitaxel (PTX) was developed through chemical conjugation of PTX to a low molecular weight chitosan (LMWC). The LMWC-PTX conjugate contained similar to 12 wt % PTX and showed greatly enhanced water solubility (> 1 mg/mL) as compared to native PTX. The conjugate showed comparable IC(50) values to that of the parent PTX against human cancer cell lines. The pharmacokinetic data revealed similar to 42% of bioavailability after oral administration of 5 mg PTX/kg of the conjugate. When the conjugate (10 mg/kg based on PTX content) was administered orally to mice bearing xenograft or allograft tumors, the conjugate-treated group showed significant inhibition of tumor growth, which was comparable to that seen with PTX of the clinically available injected form, formulated in cremophor EL/ethanol (iv) but with much lower toxicity. Tracking I(125)-labeled conjugate showed that LMWC-PTX was likely to be absorbed mainly from the ileum and reach the blood as the intact conjugate. | - |
dc.language | English | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | DRUG-DELIVERY | - |
dc.subject | PHASE-I | - |
dc.subject | MULTIDRUG-RESISTANCE | - |
dc.subject | COMPLETE REGRESSION | - |
dc.subject | ANTITUMOR-ACTIVITY | - |
dc.subject | CREMOPHOR-FREE | - |
dc.subject | CANCER | - |
dc.subject | TAXOL | - |
dc.subject | ABSORPTION | - |
dc.subject | PRODRUGS | - |
dc.title | Conjugated Chitosan as a Novel Platform for Oral Delivery of Paclitaxel | - |
dc.type | Article | - |
dc.identifier.wosid | 000260102700020 | - |
dc.type.rims | ART | - |
dc.citation.volume | 51 | - |
dc.citation.issue | 20 | - |
dc.citation.beginningpage | 6442 | - |
dc.citation.endingpage | 6449 | - |
dc.citation.publicationname | JOURNAL OF MEDICINAL CHEMISTRY | - |
dc.identifier.doi | 10.1021/jm800767c | - |
dc.contributor.localauthor | Jon, Sangyong | - |
dc.contributor.nonIdAuthor | Lee, Eunhye | - |
dc.contributor.nonIdAuthor | Lee, Jinju | - |
dc.contributor.nonIdAuthor | Lee, In-Hyun | - |
dc.contributor.nonIdAuthor | Yu, Mikyung | - |
dc.contributor.nonIdAuthor | Kim, Hyungjun | - |
dc.contributor.nonIdAuthor | Chae, Su Young | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | PHASE-I | - |
dc.subject.keywordPlus | MULTIDRUG-RESISTANCE | - |
dc.subject.keywordPlus | COMPLETE REGRESSION | - |
dc.subject.keywordPlus | ANTITUMOR-ACTIVITY | - |
dc.subject.keywordPlus | CREMOPHOR-FREE | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | TAXOL | - |
dc.subject.keywordPlus | ABSORPTION | - |
dc.subject.keywordPlus | PRODRUGS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.